Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium-188 hyaluronic acid
- Development stage
- Preclinical
- Lead developer
- Università di Padova
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Rhenium-188 hyaluronic acid** is an experimental liver-targeted therapeutic radiopharmaceutical consisting of the beta-emitting radionuclide rhenium-188 complexed with hyaluronic acid. It was developed in preclinical studies for hepatocellular carcinoma, where hyaluronic-acid receptor-mediated hepatic uptake is intended to concentrate beta radiation in the liver and induce localized radiotoxic injury. In mice, the complex showed rapid blood clearance, substantial liver accumulation, and preclinical liver dosimetry and toxicity characterization; it has not been established as an approved therapy. ([sciencedirect.com](https://www.sciencedirect.com/science/article/abs/pii/S0969805109001176))
- Other names
- (188)Re-HA188Re-HA188Re-hyaluronic acidRe-188-hyaluronic acidRe188-hyaluronic acidRe 188-hyaluronic acidrhenium-188 hyaluronic acidrhenium188 hyaluronic acidrhenium 188 hyaluronic acid
02
Targets
CD44 (CD44 antigen)DNA
Beyond the preview
Go deeper on rhenium-188 hyaluronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium-188 hyaluronic acid.